2018.01.12
License Agreement Has Been Entered between iPS Academia Japan, Inc. and myriamed GmbH
License-Out
iPS Academia Japan, Inc.:
We executed a non-exclusive license agreement with myriamed GmbH, Germany which provides services in drug development using iPS cell-derived cells, on the patents related to the iPS cell technology that have been sublicensed to us by Kyoto University.
myriamed GmbH:
We are excited about the execution of a license agreement with iPS Academia Japan, Inc., and look forward to merging the exciting reprogramming technology originally developed by Nobel laureate Prof. Shinya Yamanaka with our proprietary phenotypic heart muscle screening platform.